Jefferies maintained a Buy rating on Thermo Fisher Scientific TMO and increased its price target from $63 to $64.
Jefferies remarked, “TMO's 2Q12 adj. EPS of $1.22 was $0.06 ahead of consensus on notable core revenue upside that flowed at respectable incremental OP margins (32%; in line); the recast of its Hamilton Lab Workstations unit (pending divestiture) to discontinued ops accounted for $0.02 of the upside. We are raising our 2012 EPS forecast to $4.80 (from $4.75) on the better 2Q12 experience. Our PT moves to $64 (from $63) on higher cash flow forecasts.”
Thermo Fisher Scientific closed at $54.14 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in